• MOU Lends Support to Future Clinical Trial at Dundee
    John Dillon

News & Views

MOU Lends Support to Future Clinical Trial at Dundee

Feb 03 2020

Clinical stage drug development company Evgen Pharma, focused on the treatment of cancer and neurological conditions, has entered into a Memorandum of Understanding with the University of Dundee to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (“NASH”) and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University’s School of Medicine.

With the assistance of Evgen, Professor Dillon will lead the process to secure appropriate grant funding and obtain clinical trial regulatory approval. The intention is to utilise advanced MRI scanning technology to investigate whether SFX-01 can reverse the hallmarks of NASH in a proof-of-concept clinical trial. Clinical data arising from a successful trial will support subsequent development, regulatory approval and commercialisation of SFX-01 in NASH and liver fibrosis. Evgen will be granted an option to the clinical data on fair commercial terms to enable it to advance development and commercialisation.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee’s the School of Medicine said: “We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology.”

Dr Stephen Franklin, CEO of Evgen Pharma, commented: “As a result of the successful fundraise in April of this year, we are now in a position to be able to expand the toxicology package for SFX-01 which is a prerequisite to being able to support the trial design proposed by Professor Dillon and colleagues. We are particularly excited by this trial design because of the use of advanced MRI imaging of the liver which will give an objective measure of the extent to which SFX-01 can modulate the pathology of the disease.”


Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions

Events

Microbiology Society Annual Conference 2024

Apr 08 2024 Edinburgh 2024

analytica 2024

Apr 09 2024 Munich, Germany

ChemBio Finland 2024

Apr 10 2024 Helsinki, Finland

Analytica Anacon India & IndiaLabExpo

Apr 15 2024 Mumbai, India

Analitika Expo 2024

Apr 16 2024 Moscow, Russia

View all events